alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 451–475 of 1,376 studies published 2021 (page 19 of 56) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults

✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA network open 2021-07-01

Amyloid PET and sleep duration information was acquired on 4425 cognitively unimpaired participants (mean [SD] age, 71.3 [4.7] years; 2628 [59.4%] female; 1509 [34.1%] tested Aβ positive). 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT)

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer disease and associated disorders 2021-04-01

Regional sex-related differences in tau PET burden may contribute to the disparities in AD prevalence between males and females. 4 key findings →

Design: cross-sectional Participants: 148 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Memory Impairment With Concomitant Tau Pathology in Patients With Cerebral Amyloid Angiopathy

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Neurology 2021-02-24

These results suggest that the presence of objective memory impairment in patients with probable CAA could serve as a marker for underlying tau pathology. 4 key findings →

Design: cross-sectional Participants: 39 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Psychoeducational Program for the Family Member Caregivers of People with Dementia to Reduce Perceived Burden and Increase Patient's Quality of Life: A Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of primary care & community health 2021-01-01

Psychoeducational program is effective in reducing the family caregivers' perceived burden. 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. BMC neuroscience 2021-08-06

An eight-week course of IVIG totaling 2 g/kg in MCI is safe but is not sufficient to sustain an initial reduction in brain atrophy or a temporary delay in conversion to dementia at five years. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

ESO Guideline on covert cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. European stroke journal 2021-05-11

'Covert' cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2021-07-26

No large-scale characterizations of neurofilament light chain (NfL) have been conducted in diverse populations. 1 key finding →

Participants: 890 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

GPS driving: a digital biomarker for preclinical Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's research & therapy 2021-06-14

The findings suggest that GPS driving may serve as an effective and accurate digital biomarker for identifying preclinical AD among older adults. 2 key findings →

Participants: 64 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine-learning-based COVID-19 mortality prediction model and identification of patients at low and high risk of dying

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Critical care (London, England) 2021-09-08

An accurate COVID-19 mortality prediction model among hospitalized patients based on the clinical features and comorbidities may play a beneficial role in the clinical setting to better management of patients with COVID-19. 3 key findings →

Participants: 250 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Detection of dementia on voice recordings using deep learning: a Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's research & therapy 2021-08-31

This proof-of-concept study demonstrates that automated deep learning-driven processing of audio recordings of neuropsychological testing performed on individuals recruited within a community cohort setting can facilitate dementia screening. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning Algorithms and Statistical Approaches for Alzheimer's Disease Analysis Based on Resting-State EEG Recordings: A Systematic Review

✓ Peer-reviewed alzhub usefulness score 55 out of 100. International journal of neural systems 2021-02-16

Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common type of dementia with a great prevalence in western countries. 1 key finding →

Participants: 49 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The Lancet. Neurology 2021-08-01

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Science (New York, N.Y.) 2021-06-01

Stress granules are dynamic, reversible condensates composed of RNA and protein that assemble in eukaryotic cells in response to a variety of stressors and are normally disassembled after stress is removed. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Activated microglia mitigate Aβ-associated tau seeding and spreading

✓ Peer-reviewed alzhub usefulness score 55 out of 100. The Journal of experimental medicine 2021-06-08

In Alzheimer's disease (AD) models, AD risk variants in the microglial-expressed TREM2 gene decrease Aβ plaque-associated microgliosis and increase neuritic dystrophy as well as plaque-associated seeding and spreading of tau aggregates. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes

✓ Peer-reviewed alzhub usefulness score 55 out of 100. NPJ Parkinson's disease 2021-10-11

Neurofilament light chain (NfL) and α-synuclein oligomeric seeds (α-syn-s) are promising biomarkers for patients with parkinsonism. 4 key findings →

Participants: 153 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Deep Learning-Based Classification and Voxel-Based Visualization of Frontotemporal Dementia and Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in neuroscience 2021-01-21

Frontotemporal dementia (FTD) and Alzheimer's disease (AD) have overlapping symptoms, and accurate differential diagnosis is important for targeted intervention and treatment. 4 key findings →

Participants: 4,099 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Neurology 2021-12-22

Experimental studies suggest that the balance between short and long β-amyloid (Aβ) species might modulate the toxic effects of Aβ in Alzheimer disease (AD), but clinical evidence is lacking. 4 key findings →

Participants: 656 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Past, Present, and Future of Non-invasive Brain Stimulation Approaches to Treat Cognitive Impairment in Neurodegenerative Diseases: Time for a Comprehensive Critical Review

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Frontiers in aging neuroscience 2021-01-20

We here review evidence gathered for nearly a decade on non-invasive brain stimulation (NIBS), a less known therapeutic strategy aiming to limit cognitive decline associated with neurodegenerative conditions. 1 key finding →

Participants: 70 Evidence: high

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed